Sonmez Dogancan, Hocaoglu Cicek
Rize State Hospital, Clinic of Psychiatry, Rize, Türkiye.
Department of Psychiatry, Recep Tayyip Erdoğan University Faculty of Medicine, Rize, Türkiye.
Eurasian J Med. 2024 Oct 23;56(3):199-204. doi: 10.5152/eurasianjmed.2024.24409.
Pregnancy is a period in a woman's life during which she experiences physiological, psychological, and social changes. These changes can lead to various mental illnesses, including postpartum depression (PPD), which is common during the perinatal period. Postpartum depression is a significant cause of morbidity and mortality for both the mother and baby. A peripartum-onset major depressive episode is defined as PPD when it occurs during pregnancy or up to 4 weeks postpartum. The frequency of this condition is extremely high. Its etiology is influenced by biological, psychological, and sociocultural factors. Depressed mood, anhedonia, feelings of guilt, irritability, lack of concentration, psychomotor agitation or retardation, sleep disturbance, and changes in appetite and weight can all be symptoms of PPD. There are various treatment options available, many of which are adapted from those used for major depression. Selective serotonin reuptake inhibitors, serotonin-noradrenaline reuptake inhibitors, tricyclic antidepressants, estradiol, progesterone, psychotherapies, electroconvulsive therapy, and brexanolone can be used to treat PPD. In addition, the newest drug approved by the FDA (Food and Drug Administration) for this condition is oral zuranolone. This review aims to analyze recent developments on zuranolone, the latest drug approved by the FDA for PPD, based on current studies.
怀孕是女性生命中的一个阶段，在此期间她会经历生理、心理和社会方面的变化。这些变化可能导致各种精神疾病，包括产后抑郁症（PPD），这在围产期很常见。产后抑郁症是导致母亲和婴儿发病和死亡的一个重要原因。当在孕期或产后4周内发生时，围产期起病的重度抑郁发作被定义为产后抑郁症。这种疾病的发生率极高。其病因受生物学、心理学和社会文化因素影响。情绪低落、快感缺失、内疚感、易怒、注意力不集中、精神运动性激越或迟缓、睡眠障碍以及食欲和体重变化都可能是产后抑郁症的症状。有多种治疗选择，其中许多是借鉴用于重度抑郁症的治疗方法。选择性5-羟色胺再摄取抑制剂、5-羟色胺-去甲肾上腺素再摄取抑制剂、三环类抗抑郁药、雌二醇、孕酮、心理治疗、电休克疗法和布雷沙诺龙都可用于治疗产后抑郁症。此外，美国食品药品监督管理局（FDA）批准用于这种疾病的最新药物是口服的祖拉诺龙。本综述旨在根据当前研究分析FDA批准用于产后抑郁症的最新药物祖拉诺龙的最新进展。
